Orthocell Limited (ASX:OCC)
Australia flag Australia · Delayed Price · Currency is AUD
1.015
+0.005 (0.49%)
Dec 5, 2025, 4:10 PM AEST

Orthocell Company Description

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair.

The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications.

Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Orthocell Limited
Orthocell logo
Country Australia
Founded 2006
Industry Biotechnology
Sector Healthcare
CEO Paul Anderson

Contact Details

Address:
Building 191
Murdoch, 6150
Australia
Phone 61 8 9360 2888
Website orthocell.com

Stock Details

Ticker Symbol OCC
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU000000OCC6
SIC Code 2836

Key Executives

Name Position
Paul Frederick Anderson Chief Executive Officer, MD and Executive Director
Jim Piper Chief Financial Officer
Alex McHenry Chief Operating Officer
Prof. Ming Hao Zheng Chief Scientific Officer and Member of Medical and Scientific Advisory Board
John Walker Vice President of Sales
Kevin Leach Head of Marketing
Tony Macintyre Chief Technical Operations Officer
Adam Wood Chief Commercial Officer
Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary